Condition
Craniopharyngiomas
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 3 (2)
P 4 (1)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06970145Phase 1RecruitingPrimary
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
NCT02860923Phase 3CompletedPrimary
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
NCT02190994Phase 4Unknown
Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions
NCT00306683Phase 3Completed
Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions
Showing all 4 trials